Neurodegenerative disease patients have few treatment options, which often provide only limited effectiveness. Companies that can invest in and develop new, tolerable therapies which improve patients.
Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children.
2008-05-13, 514 views, By Mary Ann Liebert, Inc., publishers
By Senator Suzanne Chun Oakland, Chair Human Services Committee, in order to protect Hawaiians' Health, this resolution is the result of Hawaiians' anger at tabling of two bills to ban aspartame outright because of corporate lobbyists' pressures.
2008-03-12, 1888 views, By New Millennium Fine Art